News

October 31, 2012 — Boston Scientific Corp. received CE mark approval for the Synergy everolimus-eluting...

The Cardiovascular Research Foundation (CRF) announced the late-breaking trials and first report investigations that will be presented at next month's ...

As the average age of the U.S. population and the number of patients at high risk for cardiovascular disease increase, the usage of cardio and endovascular stents continues to grow. Interventional...

June 21, 2012 — Plans for a new study involving BioFreedom, the polymer-free drug-coated stent (DCS) from Biosensors, were announced  at EuroPCR by principal investigator Dr. Philip Urban,...

June 15, 2012 — Stentys SA, a medical technology company commercializing the world's first and only self-apposing stent to treat acute myocardial infarction (AMI), announced that it has...

Evaluating the performance of your cath lab is key to developing a strategic plan for improving service offerings, planning growth and expanding market share to compete for revenues. Availability...

June 4, 2012 — Boston Scientific Corp. has received U.S. Food and Drug Administration (FDA) regulatory approval of 32 mm and 38 mm lengths for the Promus Element Plus everolimus-eluting...

May 30, 2012 - According to study results to be featured in the late-breaking clinical trials session at the American Association of Clinical Endocrinologists (AACE) 21st Annual Scientific...

May 23, 2012 — Boston Scientific Corp. announces that the Synergy everolimus-eluting bioabsorbable polymer-coated platinum chromium coronary stent demonstrated noninferior results in treating...

May 23, 2012 — Boston Scientific Corp. announced two-year results from the PLATINUM Small Vessel study, demonstrating excellent safety and effectiveness outcomes for the 2.25 mm Promus Element...

May 22, 2012 — New long-term data from the DIVERGE study presented at EuroPCR 2012 showed that the use of the Axxess...

May 15, 2012 –– As EuroPCR 2012 gets underway, Medtronic Inc.announced that the Resolute Integrity Coronary Stent System has received European regulatory approval for several new indications...

April 12, 2012 – Abbott announced approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for the next-generation Xience Prime Everolimus-Eluting Coronary Stent System for the...

April 6, 2012 — Boston Scientific Corp. announced results from a quantitative coronary angiographic (QCA) analysis of the incidence of longitudinal stent deformation in the PERSEUS and PLATINUM...

Boston Scientific announced its support of the HORIZONS II AMI clinical trial, which is designed to evaluate the safety and efficacy of the Promus Element Plus everolimus-eluting platinum chromium...

Two-year follow-up data from the pivotal PLATINUM Workhorse trial comparing the safety and effectiveness of the Promus Element and Xience V everolimus-eluting coronary stents demonstrated superior...

March 29, 2012 — In the second year of an ongoing trial, the Resolute zotarolimus-eluting stent (Medtronic) achieved a low rate of stent thrombosis, cardiac death, target vessel heart attack and...

Biodegradable polymer drug-eluting stents (DES) provide better long-term safety and efficacy than durable polymer DES, according to findings from an analysis of three major clinical trials — ISAR-...

March 9, 2012 — Boston Scientific Corp. announced the launch of the Promus Element everolimus-eluting coronary stent system in Japan. The product was recently approved by the Ministry of Health,...